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Cellular-Src (c-Src) encodes a plasma membrane–associated
tyrosine protein kinase, which plays a vital role in signaling
pathways related to cellular development and carcinogenesis
(1,2). It was the ﬁrst proto-oncogene to be described and is the
cellular homologue in humans of the viral oncogene of Rous
sarcoma virus, the chicken tumor virus discovered by Peyton
Rous in 1911 (3). More recently, c-Src has been implicated in
connexin43 (Cx43) remodeling in epicardial border zone
myocytes following myocardial infarction (MI) (4).
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Cx43 is the major ventricular gap junction protein in
mammalian hearts, and the intercellular coupling mediated
by these gap junctions allow for normal electrical conduction
(5–7). Cx43 interacts with a scaffolding protein zonula-
occludens-1 (ZO-1) to localize at intercalated disks (8,9).
After a MI, phosphorylation of c-Src leads to its activation
(p-Src), which then disrupts the ZO-1/Cx43 interaction
(4,10). Displacement of the Z0-1/Cx43 interaction can
cause Cx43 relocalization from the intercalated disks to
myocyte lateral membranes (4,11). Cx43 lateralization in the
infarct border zone is associated with altered gap junction
coupling and is believed to be an important mechanism
underpinning electrical conduction slowing and the devel-
opment of reentrant arrhythmias (12).
Sovari et al. (11) have previously shown that 1-(1,1-
dimethylethyl)-1-(4-methylphenyl)-1H-pyrazolo[3,4-d] pyr-
imidin-4-amine (PP1), a c-Src inhibitor, can increase Cx43
levels at gap junctions, improve gap junction function,
and reduce inducibility of ventricular tachycardia (VT) in
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contents of this paper to disclose.mice. Activation of the renin-angiotensin system in these mice
led to c-Src up-regulation, loss of Cx43 and gap function
coupling, and arrhythmogenesis; these processes were miti-
gated by inhibition of c-Src (11) (Fig. 1).
In this issue of the Journal, Rutledge et al. (13) expand on
these prior ﬁndings by applying our current understanding
of post-MI Cx43 pathophysiology and hypothesizing that
inhibition of c-Src activation can improve Cx43 levels and
thereby ameliorate arrhythmia inducibility following MI.
Mice undergoing MI after coronary artery ligation were
treated with c-Src inhibitors PP1 and AZD0530, which is
currently in clinical development and has been used to treat
human cancers (14,15). The authors showed that c-Src in-
hibition moderated Cx43 down-regulation after MI com-
pared with infarcts in mice treated with an inactive analogue
or with saline. In addition, the restoration in Cx43 levels
in mice treated with c-Src inhibitors was correlated with
observed ﬁndings of lower p-Src levels, enhanced conduc-
tion velocity, and reduced arrhythmia inducibility in these
MI mice. Interestingly, the improved Cx43 levels did not
appear to be due to redistribution of Cx43, but rather to PP1
effects on increased Cx43 transcription as well as decreased
Cx43 degradation. Furthermore, the authors’ results suggest
that the underlying post-MI mechanisms leading to reduced
Cx43 levels and c-Src activation are similarly triggered
throughout the myocardium, rather than being contained
only to peri-infarct tissue.
Rutledge et al. (13) should be commended for continuing
to elucidate a novel approach toward a potential new anti-
arrhythmic therapy via inhibition of c-Src. They have added
to a growing literature of studies seeking to modulate
gap junction remodeling in order to decrease post-infarct
arrhythmias. These studies include targeted Cx43 gene
transfer to a porcine infarct model (16), engraftment of
Cx43-expressing embryonic cardiomyocytes post-infarct
(17), use of growth hormone-releasing peptide to modu-
late Cx43 levels (18), and use of heavy ion radiation to up-
regulate Cx43 levels (19,20).
However, further investigation will be necessary. Notably,
post-translational phosphorylation is critical to almost all
aspects of Cx43 regulation and gap junction function
(21,22). The authors did ﬁnd that c-Src inhibition increased
slowly migrating forms of Cx43, which are felt to be related
to phosphorylated Cx43 that are associated with enhanced
gap junction function (23,24). Nevertheless, further studies
are needed to understand the precise mechanisms and sites
of Cx43 phosphorylation, and how c-Src inhibition relates
to these different forms of Cx43. In addition, as the authors
point out, although they found a beneﬁcial outcome by using
c-Src inhibitors after 2 weeks post-MI, the effects of c-Src
inhibition immediately after an ischemic event has not be
examined and, in fact, could be harmful. There is data to
suggest that Cx43 down-regulation after an MI may be
adaptive because restricting gap junction communication
may prevent the spread of deleterious by-products of
ischemia and thereby limit infarct size (25). Hence, the
Figure 1 Scheme of c-Src Kinase Pathway Modulating Cx43
Angiotensin II (Ang II) activates and up-regulates c-Src, which in turn causes a dysregulation and degradation of connexin43 (Cx43) with impaired gap junction function. PP1
inhibits c-Src kinase and interrupts Ang II–mediated Cx43 reduction, myocyte uncoupling, and sudden arrhythmic death. ATR-1 ¼ angiotensin II type 1 receptor; RAS ¼ renin-
angiotensin system; VF ¼ ventricular ﬁbrillation; VT ¼ ventricular tachycardia; ZO ¼ zonula-occludens. Reproduced with permission from Sovari et al. (11).
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936timing of c-Src inhibition is important; furthermore, dura-
tion of treatment will need to be determined because cardiac
Cx43 has a relatively short half-life of about 1 to 2 h (26,27),
and the substrate for arrhythmia may persist beyond the
2-week period after an MI. In addition, there are concerns
about QT prolongation with this class of tyrosine kinase
inhibitors (28), and it is not uncommon for a purportedly
antiarrhythmic therapy to have pro-arrhythmic effects
instead. Hence, more studies are needed to better under-
stand these potential side effects due to tyrosine kinase in-
hibitors, including the risks of left ventricular dysfunction
and hypertension (both systemic and pulmonary) (29,30).
The long-term outcomes and possible cardiovascular side
effects of this class of drugs are therefore still unknown for
an already potentially vulnerable patient population. Finally,
the clinical applicability of a mouse model has its limitations
such that the role of c-Src inhibition in a larger animal
infarct model is necessary.
In conclusion, c-Src and its importance in tumorigenesis
have been widely studied. The ﬁndings of Rutledge et al.
(13) have provided further insight into the role of c-Src
inhibition and arrhythmogenesis. Furthermore, although
PP1 is not used clinically, AZD0530 has been studied in
several phase 1 and 2 human cancer trials and is therefore
closer to clinical application (31–33). The analogy to
tumorigenesis and cancer therapeutics may be appropriately
ﬁtting. Ventricular arrhythmias are believed to result from
multiple factors and stochastic events; thus far, the mainstay
treatments have involved relatively blunt tools including
internal deﬁbrillators, radiofrequency ablation of infarctborder zones, and antiarrhythmic drug therapies nonspe-
ciﬁcally targeting various ion channels. Similarly, until the
advent of mechanistic-driven therapeutics, oncologic treat-
ments have tended to involve surgical resection, radiation
therapy, and relatively nondiscerning chemotherapy that can
collaterally affect normal tissue while not fully targeting the
underlying cause(s). However, over the last decades, ad-
vances in the understanding of the underlying molecular
processes involved in tumorigenesis have contributed to
more speciﬁc and precise therapeutics for a variety of can-
cers. Analogously, although it is not clear that c-Src inhi-
bition or even modulating Cx43 after an infarct will be the
key to reducing arrhythmias, studies such as this from
Rutledge et al. (13) seeking mechanism-based therapies for
ventricular arrhythmias provide further optimism that we are
one step closer to an effective antiarrhythmic treatment.
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